These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29561309)

  • 1. Acute myositis: an unusual and severe side effect of docetaxel: a case report and literature review.
    Rochigneux P; Schleinitz N; Ebbo M; Aymonier M; Pourroy B; Boissier R; Salas S; Deville JL
    Anticancer Drugs; 2018 Jun; 29(5):477-481. PubMed ID: 29561309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel-induced acute myositis: a case report with review of literature.
    Wongsaengsak S; Quirch M; Ball S; Sultan A; Jahan N; Elmassry M; Rehman S
    J Chemother; 2021 Apr; 33(2):116-121. PubMed ID: 32619151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grade IV myositis: A rare complication of docetaxel.
    Saini R; Chandragouda D; Talwar V; Rajpurohit S
    J Cancer Res Ther; 2015; 11(3):664. PubMed ID: 26458695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rare case of docetaxel-induced myositis in a patient with a lung adenocarcinoma.
    Ishida A; Ushio A; Hashimoto M; Ishii S; Naka G; Iikura M; Izumi S; Hojo M; Sugiyama H
    Thorac Cancer; 2022 Jul; 13(14):2075-2077. PubMed ID: 35595502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
    Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel.
    Buttigliero C; Tucci M; Vignani F; Di Stefano RF; Leone G; Zichi C; Pignataro D; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Clin Genitourin Cancer; 2018 Aug; 16(4):318-324. PubMed ID: 29866495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
    van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
    Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer.
    Takahashi M; Kusuhara Y; Mori H; Komori M; Kagawa J; Fukawa T; Yamamoto Y; Yamaguchi K; Fukumori T; Kanayama H
    Clin Genitourin Cancer; 2015 Aug; 13(4):e337-e340. PubMed ID: 25770768
    [No Abstract]   [Full Text] [Related]  

  • 12. Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System.
    Singh P; Nayernama A; Christopher Jones S; Amiri Kordestani L; Fedenko K; Prowell T; Bersoff-Matcha SJ
    J Oncol Pharm Pract; 2020 Jun; 26(4):923-928. PubMed ID: 31594460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
    Nilsson S
    Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
    Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
    Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
    Parimi S; Eliasziw M; North S; Trudeau M; Winquist E; Chi KN; Ruether D; Cheng T; Eigl BJ
    Invest New Drugs; 2016 Dec; 34(6):771-776. PubMed ID: 27565809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
    Thomas C; Brandt MP; Baldauf S; Tsaur I; Frees S; Borgmann H; Jäger W; Bartsch G; Schneider M; Dotzauer R; Neisius A; Haferkamp A
    Int Urol Nephrol; 2018 Oct; 50(10):1821-1827. PubMed ID: 30120678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
    Szarvas T; Sevcenco S; Módos O; Keresztes D; Nyirády P; Kubik A; Romics M; Kovalszky I; Reis H; Hadaschik B; Shariat SF; Kramer G
    Urol Oncol; 2018 Jun; 36(6):312.e9-312.e15. PubMed ID: 29628317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fatal neutropenic enterocolitis in a patient with castration-resistant prostate cancer treated with first-line chemotherapy].
    Kongsted P; Sheikh K; Mouritsen LS; Lindberg H; Sengeløv L
    Ugeskr Laeger; 2015 Jan; 177(2A):24-5. PubMed ID: 25612951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
    Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
    Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.